{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:14:55Z","timestamp":1765354495542},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.5815","type":"journal-article","created":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T18:09:02Z","timestamp":1473876542000},"page":"2707-2712","source":"Crossref","is-referenced-by-count":3,"title":["Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone"],"prefix":"10.2169","volume":"55","author":[{"given":"Yoshitaka","family":"Kikukawa","sequence":"first","affiliation":[{"name":"Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Hata","sequence":"additional","affiliation":[{"name":"Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Diagnostic Unit for Amyloidosis, Department of Neurology, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Diagnostic Unit for Amyloidosis, Department of Neurology, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Singo","family":"Nasu","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Ide","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikiko","family":"Ueno","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Ando","sequence":"additional","affiliation":[{"name":"Diagnostic Unit for Amyloidosis, Department of Neurology, Kumamoto University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okuno","sequence":"additional","affiliation":[{"name":"Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361: 1787-1789, 2003.","DOI":"10.1016\/S0140-6736(03)13396-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 119: 1117-1122, 2012.","DOI":"10.1182\/blood-2011-07-370031"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gertz MA, Lacy MQ, Dispenzieri A, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma 51: 2181-2187, 2010.","DOI":"10.3109\/10428194.2010.524329"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mohty D, Damy T, Cosnay P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 106: 528-540, 2013.","DOI":"10.1016\/j.acvd.2013.06.051"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119: 4387-4390, 2012.","DOI":"10.1182\/blood-2011-10-388462"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 119: 4391-4394, 2012.","DOI":"10.1182\/blood-2011-11-390930"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kikukawa Y, Yuki H, Hirata S, et al. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. Int J Hematol 101: 133-139, 2015.","DOI":"10.1007\/s12185-014-1705-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kastritis E, Terpos E, Roussou M, et al. A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 119: 5384-5390, 2012.","DOI":"10.1182\/blood-2011-12-396903"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 119: 4860-4867, 2012.","DOI":"10.1182\/blood-2012-01-407791"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hildebrandt G, Holler E. Acute deterioration of Charcot-Marie-Tooth disease IA (CMTIA) following 2 mg of vincristine chemotherapy. Ann Oncol 11: 743-747, 2000.","DOI":"10.1023\/A:1008369315240"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nishikawa T, Kawakami K. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 30: 519-521, 2008.","DOI":"10.1097\/MPH.0b013e31816624a4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yerushalmi R, Levi I, Wygoda M, et al. Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease? J Peripher Nerv Syst 12: 139-141, 2007.","DOI":"10.1111\/j.1529-8027.2007.00133.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Martino MA, Miller E, Grendys EC. The administration of chemotherapy in a patient with Charcot-Marie-Tooth and ovarian cancer. Gynecol Oncol 97: 710-712, 2005.","DOI":"10.1016\/j.ygyno.2005.01.017"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M. Therapy-related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 33: 113-119, 2015.","DOI":"10.1002\/hon.2149"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Seldin DC, Choufani EB, Dember LM, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 3: 241-246, 2003.","DOI":"10.3816\/CLM.2003.n.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105: 2949-2951, 2005.","DOI":"10.1182\/blood-2004-08-3231"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Desport E, Bridoux F, Sirac C, et al. AL Amyloidosis. Orphanet J Rare Dis 7: 1-13, 2012.","DOI":"10.1186\/1750-1172-7-54"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 99: 743-750, 2014.","DOI":"10.3324\/haematol.2013.095463"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 98: 433-436, 2013.","DOI":"10.3324\/haematol.2012.073593"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tazir M, Hamadouche T, Nouioua S, et al. Hereditary motor and sensory neuropathies or Charcot-Marie-Tooth diseases: An update. J Neurol Sci 347: 14-22, 2014.","DOI":"10.1016\/j.jns.2014.10.013"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 242: 47-54, 2006.","DOI":"10.1016\/j.jns.2005.11.014"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/18\/55_55.5815\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T18:48:43Z","timestamp":1498330123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/18\/55_55.5815\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":21,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.5815","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}